The clinical value of
amphotericin B, the mainstay
therapy for
visceral leishmaniasis in
sodium antimony gluconate-nonresponsive zones of Bihar, India, is now threatened by the emergence of acquired drug resistance, and a comprehensive understanding of the underlying mechanisms is the need of the hour. We have selected an
amphotericin B-resistant clinical isolate which demonstrated 8-fold-higher 50% lethal doses (LD(50)) than an
amphotericin B-sensitive strain to explore the mechanism of
amphotericin B resistance. Fluorimetric analysis demonstrated lower anisotropy in the motion of the
diphenylhexatriene fluorescent probe in the resistant strain, which indicated a higher fluidity of the membrane for the resistant strain than for the sensitive strain. The expression patterns of the two transcripts of
S-adenosyl-l-methionine:C-24-Δ-
sterol methyltransferase and the absence of
ergosterol, replaced by cholesta-5,7,24-trien-3β-ol in the membrane of the resistant parasite, indicate a decreased
amphotericin B affinity, which is evidenced by decreased
amphotericin B uptake. The expression level of MDR1 is found to be higher in the resistant strain, suggesting a higher rate of efflux of
amphotericin B. The resistant parasite also possesses an upregulated
tryparedoxin cascade and a more-reduced intracellular
thiol level, which helps in better scavenging of
reactive oxygen species produced by
amphotericin B. The resistance to
amphotericin B was partially reverted by the
thiol metabolic pathway and
ABC transporter inhibitors. Thus, it can be concluded that altered membrane composition,
ATP-binding cassette transporters, and an upregulated
thiol metabolic pathway have a role in conferring
amphotericin B resistance in clinical isolates of Leishmania donovani.